Stroke and bleeding outcomes after AF onset
| . | All AF (n = 76) . | Incident AF (n = 63) . | Recurrent AF (n = 13) . |
|---|---|---|---|
| Stroke/TIA, n (%) | 1 (1.3) | 0 | 1 (7.7) |
| Major bleeding events,* n | 8 | 7 | 1 |
| Major bleed type, no. of events | |||
| Intracranial | 2 | 2 | 0 |
| Intraocular | 2 | 2 | 0 |
| Gastrointestinal | 1 | 0 | 1 |
| Surgical | 2 | 2 | 0 |
| Other | 1 | 1 | 0 |
| Concomitant antiplatelet, n | 4 | 3 | 1 |
| Concomitant anticoagulant, n | 0 | 0 | 0 |
| Ibrutinib status after bleed, n | |||
| No change | 1 | 1 | 0 |
| Temporary hold | 6 | 6 | 0 |
| Discontinued | 1 | 0 | 1 |
| CRNMB† | |||
| CRNMB events, n | 26 | 23 | 3 |
| CRNMB type, no. of events | |||
| Genitourinary | 9 | 8 | 1 |
| Pulmonary | 3 | 2 | 1 |
| Gastrointestinal | 4 | 3 | 1 |
| Dermatologic | 4 | 4 | 0 |
| Epistaxis | 3 | 3 | 0 |
| Oral | 0 | 0 | 0 |
| Surgical | 1 | 1 | 0 |
| Ecchymosis | 0 | 0 | 0 |
| Other | 2 | 2 | 0 |
| Concomitant antiplatelet, n | 12 | 9 | 3 |
| Concomitant anticoagulant, n | 7 | 7 | 0 |
| Ibrutinib status after bleed, n | |||
| No change | 16 | 14 | 2 |
| Temporary hold | 9 | 8 | 1 |
| Discontinued | 1 | 1 | 0 |
| . | All AF (n = 76) . | Incident AF (n = 63) . | Recurrent AF (n = 13) . |
|---|---|---|---|
| Stroke/TIA, n (%) | 1 (1.3) | 0 | 1 (7.7) |
| Major bleeding events,* n | 8 | 7 | 1 |
| Major bleed type, no. of events | |||
| Intracranial | 2 | 2 | 0 |
| Intraocular | 2 | 2 | 0 |
| Gastrointestinal | 1 | 0 | 1 |
| Surgical | 2 | 2 | 0 |
| Other | 1 | 1 | 0 |
| Concomitant antiplatelet, n | 4 | 3 | 1 |
| Concomitant anticoagulant, n | 0 | 0 | 0 |
| Ibrutinib status after bleed, n | |||
| No change | 1 | 1 | 0 |
| Temporary hold | 6 | 6 | 0 |
| Discontinued | 1 | 0 | 1 |
| CRNMB† | |||
| CRNMB events, n | 26 | 23 | 3 |
| CRNMB type, no. of events | |||
| Genitourinary | 9 | 8 | 1 |
| Pulmonary | 3 | 2 | 1 |
| Gastrointestinal | 4 | 3 | 1 |
| Dermatologic | 4 | 4 | 0 |
| Epistaxis | 3 | 3 | 0 |
| Oral | 0 | 0 | 0 |
| Surgical | 1 | 1 | 0 |
| Ecchymosis | 0 | 0 | 0 |
| Other | 2 | 2 | 0 |
| Concomitant antiplatelet, n | 12 | 9 | 3 |
| Concomitant anticoagulant, n | 7 | 7 | 0 |
| Ibrutinib status after bleed, n | |||
| No change | 16 | 14 | 2 |
| Temporary hold | 9 | 8 | 1 |
| Discontinued | 1 | 1 | 0 |
Major bleed is defined as fatal bleeding, symptomatic bleeding in a critical organ (eg, intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, intramuscular), or bleeding that resulted in a hemoglobin drop of at least 2 g/dL or required at least 2 units of blood; major bleeding is reported on an event level (patients could have multiple bleeding events).
CRNMB is defined as bleeding that did not meet the ISTH criteria for major bleed but met at least 1 of the following criteria: (1) required medical intervention, (2) hospitalization, or (3) face-to-face evaluation; CRNMB is reported on an event level (patients could have multiple bleeding events).